Prof Els Van Nieuwenhuysen from UZ Leuven discussed the initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer, a rare cancer where there are no approved treatments yet.
With the educational support of:
